Sign In
Buy XNCR
$11.42
+0.210 (+1.87%)
At Close: Jun 03, 2026
The Biology Came First.
09:00am, Monday, 18'th May 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:40am, Wednesday, 13'th May 2026
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 06'th May 2026
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.
Xencor Reports First Quarter 2026 Financial Results
04:01pm, Wednesday, 06'th May 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
06:41pm, Tuesday, 05'th May 2026
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
08:01am, Monday, 04'th May 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving Average – What’s Next?
04:09am, Wednesday, 01'st Apr 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $13.44 and traded as low as $11.17. Xencor sh
Pre-Market Stock Futures: After a volatile start to the week, futures are trading lower on Tuesday. Markets had plummeted early Monday before the opening bell, only to stage a massive turnaround follo
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:32pm, Wednesday, 11'th Mar 2026
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Analysts
02:26am, Tuesday, 10'th Mar 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat.com reports. One re
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling
01:52am, Friday, 06'th Mar 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report)'s stock price gapped down before the market opened on Thursday after an insider sold shares in the company. The stock had previously closed at $12.74, but
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
06:00am, Thursday, 05'th Mar 2026
On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris.
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
04:01pm, Wednesday, 04'th Mar 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
09:06pm, Wednesday, 25'th Feb 2026
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago.
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Wednesday, 25'th Feb 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
